Future possibilities in the prevention of breast cancer: Breast cancer prevention trials
AUTOR(ES)
Cuzick, Jack
FONTE
BioMed Central
RESUMO
The available results from breast cancer chemoprevention trials are reviewed. Four trials using tamoxifen have been performed, of which three have reported efficacy results. A fifth trial using raloxifene has also been reported. The largest tamoxifen trial showed approximately 50% reduction in breast cancer incidence in the short term, but the two smaller trials did not find any reduction. Greater agreement exists for side effects; incidences of thromboembolic disease and endometrial cancers are raised approximately threefold when tamoxifen is used for 5 years. The possible reasons for the discrepancy in breast cancer reduction are explored. A review of trial parameters does not clearly explain this difference, and a meta-analysis indicates that all results are compatible with a 40% reduction in short-term incidence. Several important questions remain regarding the clinical implications of this result, including the effect on mortality, the appropriate risk groups for chemoprevention and the long-term effects on incidence. Continued follow up of these trials is crucial for resolving these issues.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=138785Documentos Relacionados
- Future possibilities in the prevention of breast cancer: Role of genetic variation in breast cancer prevention
- Future possibilities in the prevention of breast cancer: Fat and fiber and breast cancer research
- Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
- Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
- Hormonal prevention of breast cancer: Mimicking the protective effect of pregnancy